Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Valneva - Pfizer Choose Three-Dose Schedule For Lyme Vaccine Candidate Moving Forward

Valneva SE (NASDAQ:VALN) and Pfizer Inc (NYSE:PFE) have reported further Phase 2 data for their Lyme disease vaccine candidate, VLA15. 

  • The Phase 2 trial, VLA15-221, compared the immunogenicity of VLA15 after administration of two or three primary series doses. 
  • In the sub-analysis of adult participants (18-65 years old), VLA15 was immunogenic with both vaccination schedules tested. 
  • These data are consistent with the strong immunogenicity profile observed for this age group in previous Phase 2 studies. 
  • Related: Valneva, Pfizer's Phase 2 Data Suggests Booster Strategy For Lyme Disease Vaccine Candidate.
  • However, the induction of anti-OspA IgG (anti-outer surface protein A immunoglobulin G) antibody titers was higher in participants who received the three-dose primary series compared to the two-dose primary series.
  • Valneva and Pfizer plan to proceed with a three-dose primary series vaccination schedule in a planned Phase 3 trial based on these new results. 
  • The trial will evaluate VLA15 in adults and pediatric subjects five years of age and above and is expected to be initiated in 2022.
  • The VLA15-221 trial is ongoing to assess the safety and immunogenicity of VLA15 in 5-17-year-olds. Initial pediatric data are expected in 1H of 2022.
  • The analysis was also consistent with the acceptable safety and tolerability profile observed in previous studies of VLA15. 
  • No vaccine-related serious adverse events were observed.
  • Price Action: VALN shares closed at $33.56 on Thursday, while PFE stock is down 0.17% at $53.29 during the premarket session on the last check Friday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.